Cagrilintide + Semaglutide

Description

This listing combines cagrilintide and semaglutide as a co-formulated research pairing — the amylin/GLP-1 dual-hormone approach studied under the CagriSema program. Because amylin and GLP-1 act on separate receptor systems that both influence satiety, researchers use this combination to model additive or synergistic appetite-signalling effects that neither hormone produces alone.

Trial-stage data on cagrilintide+semaglutide co-administration has reported greater weight-related effect sizes than semaglutide monotherapy, which is why this pairing is increasingly requested for comparative dual-hormone research rather than single-agonist work.

Strictly for laboratory research use. Reconstitute each component with bacteriostatic water per standard protocol and store refrigerated, protected from light.